The short version of WADA Prohibited List fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-01. Anything still debated is marked as such rather than presented as settled.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
The panel noted the large number of failures to replicate excess heat and the greater inconsistency of reports of nuclear reaction byproducts expected by established conjecture. Nuclear fusion of the type postulated would be inconsistent with current understanding and, if verified, would require established conjecture, perhaps even theory itself, to be extended in an unexpected way. The panel was against special funding for cold fusion research, but supported modest funding of "focused experiments within the general funding system". Cold fusion supporters continued to argue that the evidence for excess heat was strong, and in September 1990 the National Cold Fusion Institute listed 92 groups of researchers from 10 countries that had reported corroborating evidence of excess heat, but they refused to provide any evidence of their own arguing that it could endanger their patents. However, no further DOE nor NSF funding resulted from the panel's recommendation. By this point, academic consensus had moved decidedly toward labeling cold fusion as a kind of "pathological science". In March 1990, Michael H. Salamon, a physicist from the University of Utah, and nine co-authors reported negative results. University faculty were then "stunned" when a lawyer representing Pons and Fleischmann demanded the Salamon paper be retracted under threat of a lawsuit. The lawyer later apologized; Fleischmann defended the threat as a legitimate reaction to alleged bias displayed by cold-fusion critics.
==== 12 Hour Operational Ration Pack ==== The British Armed Forces' 12 hour operational ration pack (ORP) is designed for patrolling for durations of 4–12 hours and is suitable for remote guard posts, drivers and as a supplement to normal rations for where daily calorie expenditure is likely to exceed 6000 kcal (25,120 kJ), for instance, troops undergoing arduous duties. The 12 hour ORP contains a main meal packed in a retort pouch, a number of snack items, drink powders and a flameless ration heater (FRH). However it does not contain any hot beverage items. There are 10 menu choices including one vegetarian.
=== Opposition to the Award === Basuto chiefs—including Lerotholi—welcomed the Award, and 3,000 heads of cattle were paid almost immediately as a gesture of goodwill. On 9 May 1881, Thomas Charles Scanlen replaced Sprigg as prime minister, while Basutophile Jacobus Wilhelmus Sauer was appointed as the new Secretary for Native Affairs. Scanlen encountered challenges in fully enforcing the Award, such as the erosion of the colonial administration's prestige. Masopha demanded to be granted almost arbitrary power, refusing to pay his share of the hut tax and forbidding the return of the local magistrate. Joseph Orpen, who replaced Griffith, was seen as too sympathetic to the former rebels. His handling of cattle and land compensation led to the alienation of Basuto loyalists and the departure of nearly all pre-war magistrates from Basutoland. In January 1882, Letsie I assembled an army in order to enforce the Award on Masopha, yet the expedition was cancelled as it was judged that Masopha retained considerable popular support. The Colonial Office refused to allow the Cape to abandon Basutoland and cancel the Award. Robinson then set 15 March as the new deadline for the enforcement of the Award, threatening to confiscate land from the chiefs failing to abide to it and to redistribute Quthing District to white volunteers who fought in the war. Following pleas by Letsie I and Orpen, Robinson cancelled the Award on 15 March and pledged not to confiscate land. This was followed by the repeal of the Peace Preservation Act on 6 April.
Sources: en.wikipedia.org
and Israeli military bases in the Gulf, with explosions reported in Bahrain, Iraq, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates, as well as additional spillover in Jordan and Syria. Iran war protests Anti-war protests are held in cities such as New York City, Portland, and Philadelphia. In Washington DC, anti-war protests organized by groups such as 50501 and Code Pink are held near the White House. Additionally, diaspora protests are held near the World War I Memorial with demonstrators holding American and Israeli flags praising the strikes. An anti-war protest is held in Los Angeles at the City Hall to call for an end to American military actions in the Middle East. American actress and activist Jane Fonda takes part in the protest.
=== Francium halides === Francium halides are all soluble in water and are expected to be white solids. They are expected to be produced by the reaction of the corresponding halogens. For example, francium chloride would be produced by the reaction of francium and chlorine. Francium chloride has been studied as a pathway to separate francium from other elements, by using the high vapour pressure of the compound, although francium fluoride would have a higher vapour pressure.
Despite Cleverdon's urgings, the script slipped from Thomas's priorities and in January 1951 he went to Iran to work on a film for the Anglo-Iranian Oil Company, an assignment which Callard has speculated was undertaken on behalf of British intelligence agencies. Thomas toured the country with the film crew, and his letters home vividly express his shock and anger with the poverty he saw around him. He also gave a reading at the British Council and talked with a number of Iranian intellectuals, including Ebrahim Golestan whose account of his meeting with Thomas has been translated and published. The film was never made, with Thomas returning to Wales in February, though his time in Iran allowed him to provide a few minutes of material for a BBC documentary Persian Oil. Thomas' journey through Iran has also been the subject of the 2024 documentary film Pouring Water on Troubled Oil. The film was written and directed by Nariman Massoumi, Department of Film and Television at the University of Bristol, with narration by Michael Sheen. Later that year, Thomas published two poems, which have been described as "unusually blunt." They were an ode, in the form of a villanelle, to his dying father, Do not go gentle into that good night, and the ribald Lament. Although he had a range of wealthy patrons, including Margaret Taylor, Princess Marguerite Caetani and Marged Howard-Stepney, Thomas was still in financial difficulty, and he wrote several begging letters to notable literary figures, including T. S. Eliot.
A widely cited moment from this period was her display of the WCC's Avalkoppam ("With Her") solidarity banner following a dance performance at the state government's awards ceremony in 2018, which was met with sustained applause.
Sources: en.wikipedia.org
The Russell 3000 is a stock market index tracking the stock performance of the 3,000 largest companies listed on stock exchanges in the United States. It is maintained by FTSE Russell and its components are determined via strict rules-based methodology, with an annual rebalancing in late June, the only time new entrants are added to the index. The index is a public-float-weighted/capitalization-weighted index. The index includes approximately 98% of the total market capitalization of U.S. public companies, with an aggregate market capitalization of about $75.6 trillion as of April 30, 2026. As of April 30, 2026, the median market capitalization of the components of the index is $2.8 billion and components range in market capitalization from $146 million to $4.8 trillion. Products linked to the Russell 3000 include index funds (exchange-traded funds and mutual funds) as well as derivatives (options and futures contracts), which are available for trading in many countries with the goal of replicating the performance of the index. Also available are modified index funds; they replicate the performance of the index with modifications such as the use of covered call strategies, equal weighting, performance buffers, leverage, inclusion of only growth or value stocks, or exclusion of certain sectors, all with the goal of changing the risk/return and yield.
Transmitter uptake and release: Astrocytes express plasma membrane transporters for several neurotransmitters, including glutamate, ATP, and GABA. More recently, astrocytes were shown to release glutamate or ATP in a vesicular, Ca2+-dependent manner. (This has been disputed for hippocampal astrocytes.) Regulation of ion concentration in the extracellular space: Astrocytes express potassium channels at a high density. When neurons are active, they release potassium, increasing the local extracellular concentration. Because astrocytes are highly permeable to potassium, they rapidly clear the excess accumulation in the extracellular space. If this function is interfered with, the extracellular concentration of potassium will rise, leading to neuronal depolarization by the Goldman equation. Abnormal accumulation of extracellular potassium is well known to result in epileptic neuronal activity. Trace metal homeostasis: Astrocytes are the principal regulators of trace metal homeostasis in the central nervous system. They serve as the main storage and distribution sites for copper, manganese, zinc and iron, protecting neurons from metal-induced toxicity while supplying these essential cofactors. Astrocytes accumulate copper efficiently via the high-affinity transporter CTR1 and store it bound to glutathione and metallothioneins. They export copper via the copper-transporting ATPase ATP7A, thereby supplying copper to neighbouring neurons. Astrocytes are the main storage site for manganese in the brain, accumulating roughly 50 times more Mn²⁺ than neurons.
The traditional French preparation involves placing a sugar cube on top of a specially designed slotted spoon and placing the spoon on a glass filled with a measure of absinthe. Iced water is poured or dripped over the sugar cube to mix the water into the absinthe. The final preparation contains 1 part absinthe and 3–5 parts water. As water dilutes the spirit, those components with poor water solubility (mainly those from anise, fennel, and star anise) come out of solution and cloud the drink. The resulting milky opalescence is called the louche (/luʃ/, French: 'opaque' or 'shady'). The release of these dissolved essences coincides with a perfuming of herbal aromas and flavours that "blossom" or "bloom", and brings out subtleties that are otherwise muted within the neat spirit. This reflects what is perhaps the oldest and purest method of preparation, and is often referred to as the French method. The Bohemian method is a recent invention that involves fire, and was not performed during absinthe's peak of popularity in the Belle Époque. Like the French method, a sugar cube is placed on a slotted spoon over a glass containing one shot of absinthe. The sugar is soaked in alcohol (usually more absinthe), and then set ablaze. The flaming sugar cube is then dropped into the glass, thus igniting the absinthe. Finally, a shot glass of water is added to douse the flames. This method tends to produce a stronger drink than the French method. A variant of the Bohemian method involves allowing the fire to extinguish on its own.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.